ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Appili Therapeutics Inc

Appili Therapeutics Inc (APLI)

0.04
0.005
( 14.29% )
Updated: 01:30:02

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.04
Bid
0.035
Offer
0.04
Volume
1,251
0.04 Day's Range 0.04
0.025 52 Week Range 0.06
Market Cap
Previous Close
0.035
Open
0.04
Last Trade
250
@
0.04
Last Trade Time
01:30:02
Financial Volume
-
VWAP
-
Average Volume (3m)
75,876
Shares Outstanding
121,266,000
Dividend Yield
-
PE Ratio
-0.96
Earnings Per Share (EPS)
-0.03
Revenue
6.69M
Net Profit
-3.78M

About Appili Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Halifax, Nova Scotia, Can
Founded
-
Appili Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker APLI. The last closing price for Appili Therapeutics was $0.04. Over the last year, Appili Therapeutics shares have traded in a share price range of $ 0.025 to $ 0.06.

Appili Therapeutics currently has 121,266,000 shares in issue. The market capitalisation of Appili Therapeutics is $4.24 million. Appili Therapeutics has a price to earnings ratio (PE ratio) of -0.96.

APLI Latest News

Biopharma Bucking Market Trends on Positive FDA Feedback

This firm’s treatment for a disfiguring skin infection has demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies, and shares are holding their own despite today's To...

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to...

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone...

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy...

Appili Therapeutics – Press Release Correction

HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled...

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets, and subject to the renewal of certain...

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

Your vote is important no matter how many votes you hold.Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.00514.28571428570.0350.040.0351589080.035CS
40.015600.0250.0450.0251159220.03438458CS
120.00514.28571428570.0350.0450.025758760.03277537CS
260.00514.28571428570.0350.050.025926370.03610099CS
520.00514.28571428570.0350.060.0251214520.03736174CS
156-0.74-94.87179487180.780.780.0251843400.087322CS
260-1.09-96.46017699121.131.60.0251653580.2761566CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FLNTFlint Corporation
$ 0.03
(50.00%)
675k
SFDNXT Energy Solutions Inc
$ 0.25
(42.86%)
101.5k
CVOCoveo Solutions Inc
$ 7.24
(21.68%)
894.6k
RVXResverlogix Corp
$ 0.065
(18.18%)
60.9k
VLEValeura Energy Inc
$ 5.34
(15.33%)
1.19M
AXISAxis Auto Finance Inc
$ 0.005
(-50.00%)
501k
SMCSulliden Mining Capital Inc
$ 0.02
(-20.00%)
578.24k
BKIBlack Iron Inc
$ 0.045
(-18.18%)
178.3k
WJXWajax Corporation
$ 20.59
(-17.28%)
380.74k
KRNKarnalyte Resources Inc
$ 0.12
(-14.29%)
11k
BCEBCE Inc
$ 40.05
(-1.04%)
7.31M
TWMTidewater Midstream and Infrastructure Ltd
$ 0.23
(-9.80%)
5.32M
ACAir Canada
$ 22.13
(1.79%)
3.79M
BTEBaytex Energy Corp
$ 4.30
(0.70%)
3.41M
VRNVeren Inc
$ 7.28
(1.82%)
2.73M

APLI Discussion

View Posts
BurgerKing82 BurgerKing82 4 days ago
Looks interesting
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
JUST THE BEGINNING HERE....8C BREAK SENDS THIS BIG TIME
👍️ 1
TrendTrade2016 TrendTrade2016 1 year ago
ONLY ONE?
👍️0
DTGoody DTGoody 1 year ago
Congratulations you actually got one ticker right out of hundreds. Great Job! LOL
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
BOOM...BIG VOLME OUT OF THE GATE
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
DUMMY
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
FDA!!!!!!
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
The global metronidazole market was valued at USD 1.5 billion in 2018 and is projected to reach USD 2.2 billion by 2030, growing at a CAGR of 3% during the forecast period from 2021-2030. The market for metronidazole tablets segment accounted for the largest share in 2018 with over 50% share followed by metronidazole injection segment with over 30%. The demand for metronidazole tablets segment will continue to grow due to its high usage in treatment of various diseases such as bacterial vaginosis, trichomoniasis, and amebiasis among others which are expected to drive growth during the forecast period from 2021-2030.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
The global Metronidazole market size is estimated to be worth US$ 113 million in 2021 and is forecast to a readjusted size of US$ 109.1 million by 2028 with a CAGR of -0.5% during the forecast period 2022-2030.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
FDA DECISION NEXT WEEK. LETS HOPE IT HAPPENS!!
👍️0
shurtha2000 shurtha2000 1 year ago
Huge wall@04 676,134 shares
👍️0
oldstocks oldstocks 1 year ago
Yes but the investment was for the good. Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of close-to-market opportunities that have the potential to provide near-term value with cutting-edge programs that we believe have the potential to transform how we treat many infectious diseases, addressing significant unmet medical needs in patient care.

This approach allows Appili to seek productive collaborations with industry partners and federal government agencies whose objectives align with ours, while pursuing non-dilutive funding sources specifically earmarked for infectious diseases development programs.
👍️ 1
DTGoody DTGoody 1 year ago
APLIF as of Year ended March of 2022 The company lost 25 million Dollars or .38 cents per share. Then as of Year ending March of 2023 they lost another 9.2 million Dollars or .08 cents per share. You Were Warned! Don't Be Schooled:

https://www.otcmarkets.com/otcapi/company/financial-report/375623/content
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
APLIF...NEXT BIO DEFENSE BEAST OUT OF HALIFAX...
👍️0

Your Recent History

Delayed Upgrade Clock